Browsing Tag

Nasdaq:HCWB

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide…

Jason Junior Dec 7, 2022

Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical Development for Cancer MIRAMAR,…

Health

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1…

Jason Junior Jan 24, 2022

MIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link…

Health

HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering

Jason Junior Jul 20, 2021

MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health…